JP2014507147A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014507147A5 JP2014507147A5 JP2013553643A JP2013553643A JP2014507147A5 JP 2014507147 A5 JP2014507147 A5 JP 2014507147A5 JP 2013553643 A JP2013553643 A JP 2013553643A JP 2013553643 A JP2013553643 A JP 2013553643A JP 2014507147 A5 JP2014507147 A5 JP 2014507147A5
- Authority
- JP
- Japan
- Prior art keywords
- aptamer
- seq
- tfpi
- binds
- pathway inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108091023037 Aptamer Proteins 0.000 claims description 51
- 102100030951 Tissue factor pathway inhibitor Human genes 0.000 claims description 32
- 108010013555 lipoprotein-associated coagulation inhibitor Proteins 0.000 claims description 32
- 239000000126 substance Substances 0.000 claims description 18
- 238000006467 substitution reaction Methods 0.000 claims description 18
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 12
- 125000003729 nucleotide group Chemical group 0.000 claims description 10
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 9
- 150000007523 nucleic acids Chemical group 0.000 claims description 9
- 208000032843 Hemorrhage Diseases 0.000 claims description 8
- 208000034158 bleeding Diseases 0.000 claims description 8
- 230000000740 bleeding effect Effects 0.000 claims description 8
- 150000001875 compounds Chemical class 0.000 claims description 6
- 230000007812 deficiency Effects 0.000 claims description 6
- 238000010348 incorporation Methods 0.000 claims description 6
- 230000004048 modification Effects 0.000 claims description 6
- 238000012986 modification Methods 0.000 claims description 6
- 239000002773 nucleotide Substances 0.000 claims description 6
- 102100022641 Coagulation factor IX Human genes 0.000 claims description 4
- 102100026735 Coagulation factor VIII Human genes 0.000 claims description 4
- 206010053567 Coagulopathies Diseases 0.000 claims description 4
- 201000003542 Factor VIII deficiency Diseases 0.000 claims description 4
- 208000009292 Hemophilia A Diseases 0.000 claims description 4
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 4
- 230000037429 base substitution Effects 0.000 claims description 4
- 208000015294 blood coagulation disease Diseases 0.000 claims description 4
- 238000007385 chemical modification Methods 0.000 claims description 4
- 230000009852 coagulant defect Effects 0.000 claims description 4
- 208000009429 hemophilia B Diseases 0.000 claims description 4
- 208000031169 hemorrhagic disease Diseases 0.000 claims description 4
- 230000002163 immunogen Effects 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- 206010067787 Coagulation factor deficiency Diseases 0.000 claims description 2
- 206010010356 Congenital anomaly Diseases 0.000 claims description 2
- 208000016988 Hemorrhagic Stroke Diseases 0.000 claims description 2
- 101000653189 Homo sapiens Tissue factor pathway inhibitor Proteins 0.000 claims description 2
- 208000034693 Laceration Diseases 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 108700009202 Plasminogen Activator Inhibitor-1 Deficiency Proteins 0.000 claims description 2
- 208000027276 Von Willebrand disease Diseases 0.000 claims description 2
- 230000005856 abnormality Effects 0.000 claims description 2
- 208000016804 acquired coagulation factor deficiency Diseases 0.000 claims description 2
- 230000001154 acute effect Effects 0.000 claims description 2
- 239000003146 anticoagulant agent Substances 0.000 claims description 2
- 229940127219 anticoagulant drug Drugs 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 208000011664 congenital factor XI deficiency Diseases 0.000 claims description 2
- 208000009190 disseminated intravascular coagulation Diseases 0.000 claims description 2
- 201000007219 factor XI deficiency Diseases 0.000 claims description 2
- 208000002085 hemarthrosis Diseases 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 230000005764 inhibitory process Effects 0.000 claims description 2
- 208000014674 injury Diseases 0.000 claims description 2
- 230000003993 interaction Effects 0.000 claims description 2
- 208000020658 intracerebral hemorrhage Diseases 0.000 claims description 2
- 238000007917 intracranial administration Methods 0.000 claims description 2
- 150000002634 lipophilic molecules Chemical class 0.000 claims description 2
- 208000019423 liver disease Diseases 0.000 claims description 2
- 230000001404 mediated effect Effects 0.000 claims description 2
- 208000007106 menorrhagia Diseases 0.000 claims description 2
- 230000035772 mutation Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims description 2
- 229940012957 plasmin Drugs 0.000 claims description 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims description 2
- 206010043554 thrombocytopenia Diseases 0.000 claims description 2
- 230000008733 trauma Effects 0.000 claims description 2
- 230000000472 traumatic effect Effects 0.000 claims description 2
- 208000012137 von Willebrand disease (hereditary or acquired) Diseases 0.000 claims description 2
- 238000000034 method Methods 0.000 description 3
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/026,165 US8598327B2 (en) | 2009-08-18 | 2011-02-11 | Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics |
| US13/026,165 | 2011-02-11 | ||
| PCT/US2012/024916 WO2012109675A1 (en) | 2011-02-11 | 2012-02-13 | Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014507147A JP2014507147A (ja) | 2014-03-27 |
| JP2014507147A5 true JP2014507147A5 (https=) | 2015-04-09 |
| JP6002691B2 JP6002691B2 (ja) | 2016-10-05 |
Family
ID=45771912
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013553643A Active JP6002691B2 (ja) | 2011-02-11 | 2012-02-13 | 組織因子経路阻害剤に対するアプタマーおよび出血障害治療薬としてのそれらの使用 |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP2673364A1 (https=) |
| JP (1) | JP6002691B2 (https=) |
| AU (1) | AU2012214148A1 (https=) |
| CA (1) | CA2827160A1 (https=) |
| WO (1) | WO2012109675A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2379600B2 (en) † | 2008-12-22 | 2020-10-14 | Novo Nordisk A/S | Antibodies against tissue factor pathway inhibitor |
| HUE047173T2 (hu) | 2010-03-01 | 2020-04-28 | Bayer Healthcare Llc | Optimalizált monoklonális ellenanyagok szöveti faktor útvonal inhibitor (TFPI) ellen |
| EP2827910A2 (en) * | 2012-03-22 | 2015-01-28 | Baxter International Inc | Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics |
| CN111411164B (zh) * | 2020-05-26 | 2022-11-01 | 中国检验检疫科学研究院 | 利用数字pcr检测番茄溃疡病菌的方法及其使用的成套试剂 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6011020A (en) | 1990-06-11 | 2000-01-04 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligand complexes |
| US5262564A (en) | 1992-10-30 | 1993-11-16 | Octamer, Inc. | Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents |
| US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US6429199B1 (en) | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| WO1998037919A1 (en) | 1997-02-28 | 1998-09-03 | University Of Iowa Research Foundation | USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS |
| US6426334B1 (en) | 1997-04-30 | 2002-07-30 | Hybridon, Inc. | Oligonucleotide mediated specific cytokine induction and reduction of tumor growth in a mammal |
| DK1009413T3 (da) | 1997-09-05 | 2007-06-11 | Univ California | Anvendelse af immunstimulerende oligonukleotider til forebyggelse eller behandling af astma |
| US6514948B1 (en) | 1999-07-02 | 2003-02-04 | The Regents Of The University Of California | Method for enhancing an immune response |
| WO2007014749A2 (en) * | 2005-07-29 | 2007-02-08 | Universiteit Van Maastricht | Regulation of tissue factor activity by protein s and tissue factor pathway inhibitor |
| WO2010071894A2 (en) * | 2008-12-19 | 2010-06-24 | Baxter International Inc. | Tfpi inhibitors and methods of use |
| FR2942232B1 (fr) * | 2009-02-19 | 2015-03-13 | Lfb Biotechnologies | Moyens pour la purification d'une proteine de la coagulation et procedes pour sa mise en oeuvre |
| IN2012DN01984A (https=) * | 2009-08-18 | 2015-07-24 | Baxter Int |
-
2012
- 2012-02-13 WO PCT/US2012/024916 patent/WO2012109675A1/en not_active Ceased
- 2012-02-13 JP JP2013553643A patent/JP6002691B2/ja active Active
- 2012-02-13 EP EP12706378.2A patent/EP2673364A1/en not_active Withdrawn
- 2012-02-13 CA CA2827160A patent/CA2827160A1/en not_active Abandoned
- 2012-02-13 AU AU2012214148A patent/AU2012214148A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019516680A5 (https=) | ||
| JP2012105650A5 (https=) | ||
| JP2011528913A5 (https=) | ||
| JP2010539945A5 (ja) | 第Ｘａ因子阻害剤に対する解毒剤およびその使用の方法 | |
| JP2014507147A5 (https=) | ||
| JP2018522563A5 (https=) | ||
| JP2020530442A5 (https=) | ||
| RU2012110221A (ru) | Аптамеры к ингибитору пути тканевого фактора и их использование в качестве терапевтических агентов при нарушениях свертываемости | |
| JP2019504112A5 (https=) | ||
| JP2010519383A5 (https=) | ||
| JP2010166916A5 (https=) | ||
| JP2018502956A5 (https=) | ||
| ATE330967T1 (de) | An her2 bindende peptidverbindungen | |
| BR112013020273A2 (pt) | oligonucleotídeos antissenso | |
| JP2012095641A5 (https=) | ||
| JP2012255007A5 (https=) | ||
| MX2009000656A (es) | Acidos nucleicos que se fijan a sdf-i. | |
| JP2010530238A5 (https=) | ||
| JP2006506942A5 (https=) | ||
| JP2017523781A5 (https=) | ||
| JP2015532097A5 (https=) | ||
| JPWO2019156137A5 (https=) | ||
| RU2002130200A (ru) | Композиции для доставки лекарственного средства | |
| JP2009534451A5 (https=) | ||
| JP2013537404A5 (https=) |